De novo hepatocellular carcinoma 18 years after liver and small bowel transplantation in a one-year-old pediatric patient.


Journal

Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574

Informations de publication

Date de publication:
03 2021
Historique:
received: 09 05 2020
revised: 30 06 2020
accepted: 02 07 2020
pubmed: 28 8 2020
medline: 5 1 2022
entrez: 27 8 2020
Statut: ppublish

Résumé

De novo HCC following transplantation in a child is a rare occurrence. Even within the adult liver transplantation population, there are a limited number of published cases. In this report, we present a case of de novo HCC found in a child, post-multivisceral transplantation. A 19-year-old boy, at the age of one, received liver and small bowel transplantation due to short gut syndrome secondary to midgut volvulus and total parenteral nutrition-associated liver disease. Eighteen years later, he was found to have a large mass involving the right hepatic dome consistent with HCC. To the best of our knowledge, this is the second reported case after gut transplantation and the third case post-liver transplantation in the pediatric population.

Identifiants

pubmed: 32844551
doi: 10.1111/petr.13820
doi:

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13820

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358-380.
Khanna R, Verma SK. Pediatric hepatocellular carcinoma. World J Gastroenterol. 2018;24(35):3980-3999.
Hadzic N, Finegold MJ. Liver neoplasia in children. Clin Liver Dis. 2011;15(2):443-462.
Kelly Deirdre, Sharif Khalid, Brown Rachel M, Morland Bruce. Hepatocellular carcinoma in children. Clin Liver Dis. 2015;19(2):433-447.
Trevisani F, Garuti F, Cucchetti A, et al. De novo hepatocellular carcinoma of liver allograft: a neglected issue. Cancer Lett. 2015;357(1):47-54.
Ramadori Giuliano, Bosio Patrizia, Moriconi Federico, Malik Ihtzaz A. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy. BMC Cancer. 2018;18(1):2.
Tamè Mariarosa, Calvanese Claudio, Cucchetti Alessandro, Gruppioni Elisa, Colecchia Antonio, Bazzoli Franco. The onset of de novo hepatocellular carcinoma after liver transplantation can be both of donor and recipient origin. a case report. J Gastrointestin Liver Dis. 2020;24(3):387-389.
Navarro Burgos JB, Lee K-W, Shin YC, et al. Inexplicable outcome of early appearance of hepatocellular carcinoma in the allograft after deceased donor liver transplantation: a case report. Transpl Proc. 2015;47(10):3012-3015.
Saab S, Zhou K, Chang EK, Busuttil RW. De novo hepatocellular carcinoma after liver transplantation. J Clin Transl Hepatology. 2015;3(4):284-287.
Allaire M, Allaire M, Sérée O, et al. De novo primary liver cancer after liver transplantation: a french national study on 15803 patients. Exp Clin Transplant. 2018;16:779-780.
Torres-Landa S, Munoz-Abraham AS, Fortune BE, et al. De-Novo hepatocellular carcinoma after pediatric living donor liver transplantation. World J Hepatol. 2017;9(36):1361-1366.
Tran P, Zhou S, Wang L, et al. De novo hepatocellular carcinoma post-multivisceral transplantation in a child. Pediatr Transplant. 2017;21(7):9.
Manzia TM, Angelico R, Gazia C, et al. De novo malignancies after liver transplantation: the effect of immunosuppressionn-personal data and review of literature. World J Gastroenterol. 2019;25(35):5356-5375.
Yanik EL, Smith JM, Shiels MS, et al. Cancer risk after pediatric solid organ transplantation. Pediatrics. 2017;139(5):e20163893.
Abu-Elmagd KM, Mazariegos G, Costa G, et al. Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks. Transplantation. 2009;88(7):926-934.
Abu-Elmagd KM, Zak M, Stamos JM, et al. De novo malignancies after intestinal and multivisceral transplantation. Transplantation. 2004;77(11):1719-1725.
Fischer SE. Recurrent and de novo malignancies following liver transplantation. Diagn Histopathol. 2012;18(7):290-296.
Yu S-B, Kim H-Y, Eo H, et al. Clinical characteristics and prognosis of pediatric hepatocellular carcinoma. World J Surg. 2005;30(1):43-50.
Angelico R, Grimaldi C, Saffioti MC, Castellano A, Spada M. Hepatocellular carcinoma in children: hepatic resection and liver transplantation. Transl Gastroenterol Hepatol. 2018;3:59.
Baumann U, Adam R, Duvoux C, et al. Survival of children after liver transplantation for hepatocellular carcinoma. Liver Transplant. 2018;24(2):246-255.
Lau CSM, Mahendraraj K, Chamberlain RS. Hepatocellular carcinoma in the pediatric population: a population based clinical outcomes study involving 257 patients from the surveillance, epidemiology, and end result (SEER) database (1973-2011). HPB Surg. 2015;2015:1-10.
Czauderna P. Adult type vs. childhood hepatocellular carcinoma? Are they the same or different lesions? biology, natural history, prognosis, and treatment. Med Pediatr Oncol. 2002;39(5):519-523.
Mcateer JP, Goldin AB, Healey PJ, Gow KW. Surgical treatment of primary liver tumors in children: outcomes analysis of resection and transplantation in the SEER database. Pediatr Transplant. 2013;17(8):744-750.
Romano F, Stroppa P, Bravi M, et al. Favorable outcome of primary liver transplantation in children with cirrhosis and hepatocellular carcinoma. Pediatr Transplant. 2011;15:573-579.
Murawski M, Weeda VB, Maibach R, et al. Hepatocellular carcinoma in children: does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? lessons learned from the SIOPEL 2 and 3 studies. J Clin Oncol. 2016;34(10):1050-1056.
Harris PS, Hansen RM, Gray ME, et al. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol. 2019;25(13):1550-1559.

Auteurs

Nathan Bryan (N)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Arash Zandieh (A)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Bhaskar Kallakury (B)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Stuart Kaufman (S)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Nada Yazigi (N)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Rafaele Girlanda (R)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Jason Hawksworth (J)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Thomas Fishbein (T)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Cal Matsumoto (C)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Alexander Kroemer (A)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Khalid Khan (K)

Department of Pediatrics, Medstar Georgetown University Hospital, Washington, DC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH